DEC 1 8 2007

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known		
Application Number	10/586,627	
Filing Date	June 20, 2007	
First Named Inventor	Tomas Cihlar	
Art Unit	1614	
Examiner Name	Not Assigned	
Attorney Docket Number	599.PFUS	

	U.S. PATENT DOCUMENTS				
Examiner	C:4=	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Cite Initials* No.1	Number-Kind Code ² (if known)		Applicant of Cited Document	nt Relevant Passages or Releval	
/SW	AA*	US-6,468,737	10-22-2002	Mason et al.	
/SW/	AB*	US-20030229225-A1	12-11-2003	Reddy et al.	
	ļ				
	<u> </u>				
					

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T⁰
/SW/	ВА	WO-02/08241	01-31-2002	Gilead Sciences Inc et al.		
		•				\vdash
						Н
						Н
<u> </u>			:			
						\sqcap
		·				H
L						4 I

Examiner Signature	/Shengjun Wang/	Date Considered	11/05/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known		
Application Number	10/586,627	
Filing Date	June 20, 2007	
First Named Inventor	Tomas Cihlar	
Art Unit	1614	
Examiner Name	Not Assigned	
Attorney Docket Number	599.PFUS	

		NON PATENT LITERATURE DOCUM	ENTS	_	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the artic magazine, journal, serial, symposium, catalog, etc.), date, page(s and/or country where publis), volume-issue number(s), publisher, city hed.			
/SW	Oncology Research, 10:523-531, (1998)				
00000	СВ	D.L. FINE et al. "Cell Culture Factors Influencing In Vitro Expression of Mouse Mammary Turmor Virus," In Vitro , 12(10):693-701 (1976)			
000000000	CC	HOLY, Antonini "Synthesis and Biological Activity of Isopo Recent Advances in Nucleossides: Chemistry and Chemo			
	CD	JOPLIN et al. "Dutular Expression of Autoantigens in Prim- Liver Disease, 17(2):97-102 (1997)			
000000000000000000000000000000000000000	CE	KAST, R.E., "Tenofovir, COX Inhibitors and Zileuton Durin Regulated TNF-Alpha Increases Antigen Driven Lymphocy Immunology, 40:297-303 (2003)			
***************************************	CF	KEEFE et al. "Advances in Liver Disease" Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003, Review in Gastroenterological Disorders 2004, United States, 4(1):36-42			
00000000000000	CG	KEOGH et al. "Human Retrovirus Associated with Aberrant Distribution Dihydrolipoamide Acetyl Transferase Component of Pyruvate Dehydrogenase Complex in Primary Biliary Cirrhosis," <i>Hepatology</i> , AASLD ABSTRACTS, 1350, October 2002 p. 500A			
000000000000000000000000000000000000000	СН	LEE et al. "Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: Use of Ursodeoxycholic Acid," <i>Current Gastroenterology Reports</i> , 1:38-41 (1999)			
8000000000	CI	LIU et al. "Identification of a Proviral Structure in Human Breast Cancer," Cancer Research, 61:1754-1759 (2001)			
0000000000	CJ	MASON et al. "Pilot Study of Single and Combination Anti-Retroviral Therapy in Patients with Primary Biliary Cirrhosis," <i>Hepatology, Late Breaking Abstracts</i> , 38(5):1324 (2003)			
	CK	MASON, Andrew "Primary Biliary Cirrhosis: New Thoughts Treatment," Current Gastroenterology Reports, 4:45-51 (2	on Pathophys		
	CL	NEUBERGER, James "Primary Biliary Cirrhosis," The Lan		79, (1997)	
888888888888888888888888888888888888888	СМ	NISHIO et al. "Comparative Studies of Antimitochondrial Autoantibodies in Sera and Bile in Primary Biliary Cirrhosis," <i>Hepatology</i> , Vol. 25, No. 5, pp. 1085-1089 (1997)			
000000000000000000000000000000000000000	CN	O'NEIL, M et al. "The Merck Index Thirteenth Edition" 2001, Merck & Co. Inc. Whitehouse Station, N.J. XP002328456, page 1631. col. 2- page 1632, col. 1			
00000	СО	O'NEIL, M. et al. "The Merck Index Thirteenth Edition" 2001. Merck & Co. Inc. Whitehouse Station, N.J. XP002328457, page 29, col. 1			
00000000	СР	WALSH et al. "Successful Treatment with Adefovir Dipivoxil in a Patient with Fibrosing Cholestatic Hepatitis and Lamivudine Resistant Hepatitis B Virus," GUT 49:436-440 (2001)			
00000000	ca	WANG et al. "Detection of Mammary Tumor Virus ENV Gene-Like Sequences in Humam Breast Cancer," Cancer Research 55:5173-579 (1995)			
V	CR	WU et al. "Monoclonal Antibody-Mediated Inhibition of HIV Polymerase Activity," The Journal of Biological Chemistry,			
/SW/	CS	XU et al. "Does a Betaretrovirus Infection Trigger Primary I 100(14):8454-8459			
Examiner		/Shengiun Wang/	Date	11/05/2010	
Signature		reference considered, whether or not citation is in conformance with MPEP 609.	Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.